Suppr超能文献

筛选清肝化瘀方中的中药有效成分及其联合化疗的抗肝癌细胞作用

Screening of QHF formula for effective ingredients from Chinese herbs and its anti-hepatic cell cancer effect in combination with chemotherapy.

作者信息

Chen Tao, Li Dan, Fu Ya-ling, Hu Wei

机构信息

Department of Traditional Chinese Medicine, Three Gorges University Medical College, Yichang, Hubei 443002, China.

出版信息

Chin Med J (Engl). 2008 Feb 20;121(4):363-8.

Abstract

BACKGROUND

Recent studies have shown that effective ingredients of Chinese herbs are used more and more widely in the treatment or co-treatment of cancers, however, they are usually used separately and there has been limited research about joint application of Chinese herbs in multi-modal treatment. The aim of this study was to screen a QHF (Q: Qingrejiedu, H: Huoxuehuayu and F: Fuzhengguben) formula for effective ingredients from Chinese medicines and assess its anti-hepatic cell cancer (HCC) effect in combination with chemotherapy.

METHODS

Six effective ingredients from Chinese medicine were selected based on the previous literature and used in the study. The QHF formula and the best ratio of ingredients were evaluated in H(22) mouse (KM) models with solid tumors and ascites tumors by uniform design and monitoring inhibition of tumor growth and survival. We then observed the anti-hepatic cell cancer (HCC) effect of QHF when combined with cisplatin (DDP) in H(22) mouse (Balb/c) models with solid tumors and ascites tumors. Evaluating of the therapeutic effect included the general condition of the mice, inhibition of tumor growth, survival, changes in body weight, thymus index, spleen index and WBC counts.

RESULTS

The optimal QHF dose ratio for anti-hepatic cell cancer treatment was: 800 mg/kg Cinobufotalin, 14 mg/kg Ginsenosides Rg3, 5.5 mg/kg PNS and 100 mg/kg Lentinan. Treatment was more efficient in inhibiting the growth of transplanted tumors in H(22) mice when using the QHF formula (55.91%) than using Cinobufotalin (33.25%), Ginsenosides Rg3 (35.11%), PNS (27.12%) or Lentinan (4.97%) separately. QHF also prolonged the life of H(22) ascites hepatic cancer mice more efficiently (38.13%) than Cinobufotalin (25.00%), Ginsenosides Rg3 (27.27%), PNS (23.30%) or Lentinan (24.43%). QHF combined with DDP could reduce DDP-induced leucopenia, spleen and thymus atrophy and other toxic reactions. Combining QHF with DDP the tumor growth inhibition reached 82.54% with a 66.83% increase in survival.

CONCLUSIONS

QHF is more efficient in anti-hepatic cell cancer treatment than the single drugs that constitute the formula. QHF combined with DDP can attenuate tumor growth and suppresses the DDP-induced toxic reactions.

摘要

背景

近期研究表明,中药有效成分在癌症治疗或联合治疗中的应用越来越广泛,然而,它们通常单独使用,关于中药在多模式治疗中的联合应用研究有限。本研究的目的是从中药中筛选一种QHF(Q:清热解毒,H:活血化瘀,F:扶正固本)配方的有效成分,并评估其与化疗联合治疗肝细胞癌(HCC)的效果。

方法

根据以往文献选择六种中药有效成分用于本研究。通过均匀设计以及监测肿瘤生长抑制和生存期,在H(22)小鼠(KM)实体瘤和腹水瘤模型中评估QHF配方及其最佳成分比例。然后,我们在H(22)小鼠(Balb/c)实体瘤和腹水瘤模型中观察QHF与顺铂(DDP)联合使用时对肝细胞癌(HCC)的治疗效果。治疗效果评估包括小鼠的一般状况、肿瘤生长抑制、生存期、体重变化、胸腺指数、脾脏指数和白细胞计数。

结果

抗肝细胞癌治疗的最佳QHF剂量比为:华蟾素800mg/kg、人参皂苷Rg3 14mg/kg、三七总皂苷5.5mg/kg和香菇多糖100mg/kg。使用QHF配方(55.91%)比单独使用华蟾素(33.25%)、人参皂苷Rg3(35.11%)、三七总皂苷(27.12%)或香菇多糖(4.97%)更有效地抑制H(22)小鼠移植瘤的生长。QHF也比华蟾素(25.00%)、人参皂苷Rg3(27.27%)、三七总皂苷(23.30%)或香菇多糖(24.43%)更有效地延长H(22)腹水型肝癌小鼠的生存期(38.13%)。QHF与DDP联合使用可减轻DDP引起的白细胞减少、脾脏和胸腺萎缩等毒性反应。QHF与DDP联合使用时,肿瘤生长抑制率达到82.54%,生存期提高66.83%。

结论

QHF在抗肝细胞癌治疗中比构成该配方的单一药物更有效。QHF与DDP联合使用可减弱肿瘤生长并抑制DDP引起的毒性反应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验